Interval between neoadjuvant chemoradiotherapy and surgery for squamous cell carcinoma of the thoracic esophagus: Does delayed surgery have an impact on outcome?

Annals of Surgery

Volumn 252, Issue 5, 2010, Pages 788-795

  Ruol, Alberto ^a   Rizzetto, Christian ^a   Castoro, Carlo ^b   Cagol, Matteo ^b   Alfieri, Rita ^b   Zanchettin, Gianpietro ^a   Cavallin, Francesco ^b   Michieletto, Silvia ^a   Da Dalt, Gianfranco ^a   Sileni, Vanna Chiarion ^b   Corti, Luigi ^b   Mantoan, Silvia ^a   Zaninotto, Giovanni ^a   Ancona, Ermanno ^a  

^a UNIVERSITY OF PADUA MEDICAL SCHOOL   (Italy)

^b VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; FLUOROURACIL; FOLINIC ACID; OXALIPLATIN; PACLITAXEL;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ANASTOMOSIS LEAKAGE; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL TRIAL; CONFERENCE PAPER; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; ESOPHAGUS; ESOPHAGUS RESECTION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NECROSIS; OPERATION DURATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SURGICAL MORTALITY; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR RECURRENCE; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; MULTIPLE CYCLE TREATMENT; RADIATION INJURY; UNSPECIFIED SIDE EFFECT;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; COMBINED MODALITY THERAPY; ESOPHAGEAL NEOPLASMS; ESOPHAGECTOMY; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOADJUVANT THERAPY; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; SURVIVAL RATE; TIME FACTORS; TREATMENT OUTCOME;

EID: 78349290054     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3181fc7f86     Document Type: Conference Paper

References (18)

1. Ruol A, Castoro C, Portale G, et al. Trends in management and prognosis for esophageal cancer surgery: twenty-five years of experience at a single institution. Arch Surg. 2009;144:247-254.
2. NCCN clinical practice guidelines in oncology. Esophageal Cancer. 2010;1. www.nccn.org. Accessed June 3, 2010.
3. Wijnhoven BP, van Lanschot JJ, Tilanus HW, et al. Neoadjuvant chemoradio-therapy for esophageal cancer: a review ofmeta-analyses [Published online ahead of print2009]. World J Surg. doi: 10.1007/s00268-009-0223-z.
4. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoad-juvant chemotherapy improves significantly the long-term survival ofpatients with resectable esophageal squamous cell carcinoma: final report of a ran-domized, controlled trial ofpreoperative chemotherapy versus surgery alone. Cancer. 2001;91:2165-2174.
5. Orringer MB, Marshall B, Chang AC, et al. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg. 2007;246:363-372.
6. Mandard AM, Dalibard F, Mandard JC, et al. Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. clinicopathologiccorrelations. Cancer. 1994;73:2680-2686.
7. Francois Y, Nemoz CJ, Baulieux J, et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: the Lyon R90-01 randomized trial. J Clin Oncol. 1999;17:2396-2402.
8. Pa°hlman L. Optimal timing of surgery after preoperative chemoradiotherapy for rectal cancer. Nat Clin Pract Oncol. 2009;6:128-129.
9. Lim SB, Choi HS, Jeong SY, et al. Optimal surgery time after preop-erative chemoradiotherapy for locally advanced rectal cancers. Ann Surg. 2008;248:243-251.
10. Tran CL, Udani S, Holt A, et al. Evaluation of safety of increased time in-terval between chemoradiation and resection for rectal cancer. Am J Surg. 2006;192:873-877.
11. Habr-Gama A, Perez RO, Proscurshim I, et al. Interval between surgery and neoadjuvant chemoradiation therapy for distal rectal cancer: does de-layed surgery have an impact on outcome? Int J Radiat Oncol Biol Phys. 2008;71:1181-1188.
12. Dolinsky CM, Mahmoud NN, Mick R, et al. Effect of time interval be-tween surgery and preoperative chemoradiotherapy with 5-fluorouracil or 5-fluorouracil and oxaliplatin on outcomes in rectal cancer. J Surg Oncol. 2007;96:207-212.
13. Moore HG, Gittleman AE, Minsky BD, et al. Rate ofpathologic complete response with increased interval between preoperative combined modality therapy and rectal cancer resection. Dis Colon Rectum. 2004;47:279-286.
14. Tulchinsky H, Shmueli E, Figer A, et al. An interval >7 weeks between neoadjuvant therapy and surgery improves pathologic complete response and disease-free survival in patients with locally advanced rectal cancer. Ann Surg Oncol. 2008;15:2661-2667.
15. Kerr SF, Norton S, Glynne-Jones R. Delaying surgery after neoadjuvant chemoradiotherapy for rectal cancer may reduce postoperative morbidity with-out compromising prognosis. Br J Surg. 2008;95:1534-1540.
16. Stitzenberg KB, Sigurdson ER, Egleston BL, et al. Centralization of can-cer surgery: implications for patient access to optimal care. J Clin Oncol. 2009;27:4671-4678.
17. Birkmeyer JD, Sun Y, Wong SL, et al. Hospital volume and late survival after cancer surgery. Ann Surg. 2007;245:777-783.
18. Gruen RL, Pitt V, Green S, et al. The effect ofprovider case volume on cancer mortality. Systematic review and meta-analysis. Ca Cancer J Clin. 2009;59:192-211.